|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Understanding the relationship of perceived social support to post-trauma cognitions and posttraumatic stress disorder显示文摘 | Donald J. Robinaugh Luana Marques Lara N. Traeger Elizabeth H. Marks Sharon C. Sung J. Gayle Beck Mark H. Pollack Naomi M. Simon | 2011 | Journal of Anxiety Disorders2011，，8： | 1 |
| 2 | The New Institutionalism and EC Governance:The Promise and Limits of Institutional Analysis显示文摘 | Mark A | 1996 | Governance:An International Journal of Policy Administration and Institutions1996，9，4： | 1 |
| 3 | Autophagy in filamentous fungi显示文摘 | Judith K. Pollack Steven D. Harris Mark R. Marten | 2008 | Fungal Genetics and Biology2008，，1： | 1 |
| 4 | Hypothyroidism and hyperthyroidism in anxiety disorders revisited: new data and literature review显示文摘 | Naomi M Simon Deborah Blacker Nicole B Korbly Saumya G Sharma John J Worthington Michael W Otto Mark H Pollack | 2002 | Journal of Affective Disorders2002，，1： | 1 |
| 5 | Eszopiclone Coadministered With Escitalopram in Patients With Insomnia and Comorbid Generalized Anxiety Disorder显示文摘 | Mark Pollack Gustavo Kinrys Andrew Krystal et al | 2008 | Arch Gen Psychiatry2008，65，5： | 1 |
| 6 | Double-blind randomized controlled study of the efficacy, safety and tolerability of eszopiclone vs placebo for the treatment of patients with post-traumatic stress disorder and insomnia显示文摘BACKGROUND Sleep disturbance is a core feature of post-traumatic stress disorder(PTSD).Given the relationship between sleep disturbance and PTSD,there has been a relative paucity of studies examining the potential therapeutic impact of using pharmacotherapy to target sleep disturbance in patients with PTSD.Eszopiclone(ESZ)is a non-benzodiazepine y-aminobutyric acid-A receptor agonist indicated for the treatment of sleep and may affect sleep in patients with PTSD.AIM To evaluate the efficacy of ESZ vs placebo(PBO)for patients with PTSD and insomnia.METHODS The study was a 12-wk,double blind,randomized controlled trial with 3 mg of ESZ(n=13)or PBO(n=12).RESULTS Patients in both arms experienced significant improvement in PTSD symptoms as assessed by the Clinician-Administered PTSD Scale for DSM-IV(CAPS):ESZ(t11=-3.12,P=0.005)and PBO(t11=-3.5,P=0.002)and by self-report with the Short PTSD Rating Interview(ESZ t11=-3.38,P=0.003 and PBO t11=-4.48,P=0.0005).There were no significant differences between treatments on the CAPS(t22=-0.13,P=0.70)or the Short PTSD Rating Interview(t22=-0.58,P=0.56).Similarly,both treated groups improved on sleep measures as assessed by the Pittsburgh Sleep Quality Index with PTSD Addendum(PSQI)and on total sleep time(TST)and sleep latency assessed by actigraphy with no significant differences between groups(PSQI t22=-0.24,P=0.81;total sleep time t10=0.13,P=0.90 and sleep latency t10=0.68,P=0.50).There was a significant correlation between improvement in sleep and overall improvement in PTSD as measured by change scores on the PSQI and CAPS,r(8)=0.79,P=0.01 for ESZ treated subjects,but not for those treated with PBO r(9)=0.16,P=0.69.Adverse events of ESZ were consistent with the known profile of the medication including dysgeusia(30%,mild),sedation(20%,mild)and headache(20%,moderate to severe).CONCLUSION Results do not support the hypothesis of a specific positive effect of ESZ compared to PBO for measures of PTSD and associated sleep disturbance. | Sheila M Dowd Alyson K Zalta Helen J Burgess Elizabeth C Adkins Zerbrina Valdespino-Hayden Mark H Pollack | 2020 | World Journal of Psychiatry2020，10，3： | 1 |
| 7 | Ki-67 Is an Independent Predictor of Metastasis and Cause-Specific Mortality for Prostate Cancer Patients Treated on Radiation Therapy Oncology Group (RTOG) 94-08显示文摘 | Bret Verhoven Yan Yan Mark Ritter Li-Yan Khor Elizabeth Hammond Christopher Jones Mahul Amin Jean-Paul Bahary Kenneth Zeitzer Alan Pollack | 2013 | International Journal of Radiation Oncology, Biology, Physics2013，，2： | 1 |
| 8 | Increased Risk of Malignancy with Adalimumab Combination Therapy, Compared to Monotherapy, for Crohn’s Disease显示文摘 | Mark T. Osterman William J. Sandborn Jean-Frederic Colombel Anne M. Robinson Winnie Lau Bidan Huang Paul F. Pollack Roopal B. Thakkar James D. Lewis | 2013 | Gastroenterology2013，，： | 1 |
| 9 | Delegation, agency and agenda - setting in the europe in the european community 显示文摘 | Mark Pollack | 1997 | International Organization1997，51，1： | 1 |
| 10 | Anxiety Symptoms Questionnaire(ASQ):development and validation显示文摘Background The Anxiety Symptoms Questionnaire(ASQ)is a brief self-report questionnaire which measures frequency and intensity of symptoms and was developed to improve assessment of anxiety symptoms in a clinical setting.We examined the reliability and validity of the ASQ in patients with anxiety disorders and/or depression,nonclinical control subjects and college students.Methods 240 outpatients with generalised anxiety disorder,social anxiety disorder,panic disorder or major depressive disorder were administered the ASQ and additional questionnaires measuring depression and anxiety,as were 111 non-clinical control subjects and 487 college students.Factor analysis,Pearson's correlation coefficients and logistic regression were used to assess reliability and validity.Test-retest reliability of the ASQ was measured using a subset who were re-administered the ASQ after 4 weeks.Results Factor analysis revealed measurement of a single dimension by the ASQ.Internal consistency and test-retest reliability were strong.The ASQ total score also significantly distinguished patients with an anxiety disorder from the clinical controls above and beyond the clinicianrated Hamilton Anxiety Scale.Conclusions The ASQ is a valid,reliable and effective self-rated measure of anxiety and may be a useful tool for screening and assessing anxiety symptoms in psychiatric as well as college settings. | Amanda Baker Naomi Simon Aparna Keshaviah Amy Farabaugh Thilo Deckersbach John J Worthington Elizabeth Hoge Maurizio Fava Mark P Pollack | 2019 | General Psychiatry2019，32，6： | 1 |
| 11 | Quetiapine augmentation of paroxetine CR for the treatment of refractory generalized anxiety disorder: preliminary findings显示文摘 | Naomi M. Simon Kathryn M. Connor Richard T. LeBeau Elizabeth A. Hoge John J. Worthington Wei Zhang Jonathan R. T. Davidson Mark H. Pollack | 2008 | Psychopharmacology2008，，4： | 1 |
| 12 | Comorbid anxiety and depression显示文摘 | Mark H Pollack MD | 2005 | J Clin Psychiatry2005，66，8： | 1 |
| 13 | Hypothyroidism and hyperthyroidism in anxiety disorders revisited: new data and literature review显示文摘 | Naomi M Simon Deborah Blacker Nicole B Korbly Saumya G Sharma John J Worthington Michael W Otto Mark H Pollack | 2002 | Journal of Affective Disorders2002，，1： | 1 |
| 14 | Eszopiclone Coad- ministered With Escitalopram in Patients With Insomnia and Comorbid Generalized Anxiety Disorder 显示文摘 | Mark Pollack Gustavo Kinrys Andrew Krystal | 2008 | Arch Gen Psychiatry2008，65，5： | 1 |
| 15 | Telomere Shortening and Mood Disorders: Preliminary Support for a Chronic Stress Model of Accelerated Aging显示文摘 | Naomi M. Simon Jordan W. Smoller Kate L. McNamara Richard S. Maser Alyson K. Zalta Mark H. Pollack Andrew A. Nierenberg Maurizio Fava Kwok-Kin Wong | 2006 | Biological Psychiatry2006，，5： | 1 |
| 16 | Gender and Public Policy in Europe: An Introduction显示文摘 | Mazur Amy G Pollack Mark A | 2009 | Comparative European Politics2009，，1： | 1 |
| 17 | Prefrontal and temporal gray matter density decreases in opiate dependence 显示文摘 | Lyoo I K Pollack Mark H | 2006 | Psychopharmacology2006，184，2： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员